PRTA
Prothena Corporation plc NASDAQ Listed Dec 18, 2012$10.52
Mkt Cap $566.3M
52w Low $4.32
84.1% of range
52w High $11.69
50d MA $9.94
200d MA $9.40
P/E (TTM)
-2.4x
EV/EBITDA
-1.1x
P/B
2.0x
Debt/Equity
0.1x
ROE
-87.0%
P/FCF
-3.1x
RSI (14)
—
ATR (14)
—
Beta
-0.33
50d MA
$9.94
200d MA
$9.40
Avg Volume
487.3K
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
77 Sir John Rogerson’s Quay · Dublin, L2 2 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | AMC | -0.45 | -0.44 | +2.2% | 9.03 | +3.9% | -0.1% | +0.4% | -0.7% | -1.7% | -4.3% | — |
| Nov 6, 2025 | AMC | -0.60 | -0.67 | -11.7% | 10.08 | +4.1% | +4.8% | +4.5% | +4.0% | +7.6% | +1.0% | — |
| Aug 4, 2025 | AMC | -1.11 | -1.86 | -67.6% | 6.94 | +1.3% | +1.3% | +14.1% | +11.2% | +10.8% | +10.5% | — |
| May 8, 2025 | AMC | -0.92 | -1.12 | -21.7% | 7.10 | -1.1% | +4.6% | +7.2% | +6.9% | -3.0% | -5.4% | — |
| Feb 20, 2025 | AMC | -1.02 | -1.08 | -5.9% | 15.25 | +4.3% | +2.0% | -0.1% | -4.1% | -4.6% | -0.8% | — |
| Nov 12, 2024 | AMC | -1.18 | -1.10 | +6.8% | 17.36 | +0.0% | -0.7% | -7.3% | -19.3% | -22.2% | -19.1% | — |
| Aug 8, 2024 | AMC | -1.05 | 1.22 | +216.2% | 19.68 | +10.0% | +4.4% | +2.2% | +1.5% | +0.5% | +6.0% | — |
| May 8, 2024 | AMC | -1.21 | -1.34 | -10.7% | 23.03 | -3.0% | -4.5% | -7.3% | -10.1% | -10.2% | -2.8% | — |
| Feb 15, 2024 | AMC | -1.23 | -1.26 | -2.4% | 28.52 | -0.2% | -1.8% | -3.5% | -5.2% | -5.5% | -4.6% | — |
| Nov 2, 2023 | AMC | -0.32 | 0.38 | +218.8% | 34.96 | +10.0% | +7.4% | +2.2% | +4.2% | +1.0% | -6.3% | — |
| Aug 3, 2023 | AMC | -0.92 | -1.03 | -12.0% | 66.53 | +5.4% | -7.3% | -5.7% | -8.4% | -7.6% | -6.2% | — |
| May 4, 2023 | AMC | -0.83 | -0.89 | -7.2% | 70.16 | -0.4% | +12.0% | +9.6% | +8.0% | +7.1% | +4.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.03 | $9.38 | +3.9% | -0.1% | +0.4% | -0.7% | -1.7% | -4.3% |
| Dec 1 | Citizens | Maintains | Market Outperform → Market Outperform | — | $10.75 | $10.98 | +2.1% | -4.5% | -3.7% | +3.9% | +3.8% | +3.0% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $10.08 | $10.49 | +4.1% | +4.8% | +4.5% | +4.0% | +7.6% | +1.0% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.08 | $10.49 | +4.1% | +4.8% | +4.5% | +4.0% | +7.6% | +1.0% |
| Oct 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.37 | $11.14 | +7.4% | +1.6% | +2.7% | +1.1% | +3.7% | +1.6% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.86 | $10.12 | +2.6% | +3.1% | +5.0% | +4.5% | +1.9% | +5.0% |
| Sep 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.20 | $8.17 | -0.4% | +0.9% | +2.3% | +0.1% | +4.3% | +3.5% |
| Aug 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.56 | $8.22 | -4.0% | -3.7% | -4.2% | -3.4% | -2.0% | -4.1% |
| Aug 28 | Chardan Capital | Maintains | Buy → Buy | — | $8.56 | $8.22 | -4.0% | -3.7% | -4.2% | -3.4% | -2.0% | -4.1% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.94 | $7.03 | +1.3% | +1.3% | +14.1% | +11.2% | +10.8% | +10.5% |
| Aug 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $6.94 | $7.03 | +1.3% | +1.3% | +14.1% | +11.2% | +10.8% | +10.5% |
| Aug 5 | Chardan Capital | Maintains | Buy → Buy | — | $6.94 | $7.03 | +1.3% | +1.3% | +14.1% | +11.2% | +10.8% | +10.5% |
| Jun 20 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $5.75 | $5.92 | +3.0% | -0.5% | +5.4% | +5.6% | +4.2% | +7.5% |
| May 28 | BofA Securities | Downgrade | Neutral → Underperform | — | $4.58 | $4.48 | -2.2% | +0.4% | +2.6% | +0.2% | +1.7% | +5.5% |
| May 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.58 | $4.79 | -27.2% | -30.4% | -30.1% | -28.6% | -30.2% | -29.2% |
| May 27 | Oppenheimer | Downgrade | Outperform → Perform | — | $6.58 | $4.79 | -27.2% | -30.4% | -30.1% | -28.6% | -30.2% | -29.2% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.58 | $4.79 | -27.2% | -30.4% | -30.1% | -28.6% | -30.2% | -29.2% |
| May 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.58 | $4.79 | -27.2% | -30.4% | -30.1% | -28.6% | -30.2% | -29.2% |
| May 27 | Chardan Capital | Maintains | Buy → Buy | — | $6.58 | $4.79 | -27.2% | -30.4% | -30.1% | -28.6% | -30.2% | -29.2% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.10 | $7.02 | -1.1% | +4.6% | +7.2% | +6.9% | -3.0% | -5.4% |
| May 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.10 | $7.02 | -1.1% | +4.6% | +7.2% | +6.9% | -3.0% | -5.4% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $7.10 | $7.02 | -1.1% | +4.6% | +7.2% | +6.9% | -3.0% | -5.4% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.63 | $15.08 | +3.1% | -0.5% | +3.4% | +8.1% | -2.1% | +2.9% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.56 | $15.57 | +0.1% | -2.1% | -6.0% | -6.5% | -2.8% | +1.6% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.25 | $15.91 | +4.3% | +2.0% | -0.1% | -4.1% | -4.6% | -0.8% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.25 | $15.91 | +4.3% | +2.0% | -0.1% | -4.1% | -4.6% | -0.8% |
| Feb 21 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $15.25 | $15.91 | +4.3% | +2.0% | -0.1% | -4.1% | -4.6% | -0.8% |
| Feb 21 | Chardan Capital | Maintains | Buy → Buy | — | $15.25 | $15.91 | +4.3% | +2.0% | -0.1% | -4.1% | -4.6% | -0.8% |
| Feb 21 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.25 | $15.91 | +4.3% | +2.0% | -0.1% | -4.1% | -4.6% | -0.8% |
| Feb 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.44 | $14.55 | +0.8% | -2.7% | -2.6% | -4.5% | -4.3% | -3.8% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.01 | $15.89 | -0.7% | -4.9% | -4.2% | -3.8% | -1.7% | -5.4% |
| Dec 19 | BofA Securities | Maintains | Neutral → Neutral | — | $11.95 | $13.75 | +15.1% | +34.0% | +27.4% | +28.3% | +28.9% | +31.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.36 | $17.36 | +0.0% | -0.7% | -7.3% | -19.3% | -22.2% | -19.1% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.73 | $16.73 | +0.0% | -0.5% | -0.3% | +0.4% | +0.8% | -0.8% |
| Oct 1 | BofA Securities | Maintains | Neutral → Neutral | — | $16.73 | $16.73 | +0.0% | -0.5% | -0.3% | +0.4% | +0.8% | -0.8% |
| Aug 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $19.98 | $20.06 | +0.4% | -1.1% | +4.5% | +4.0% | +6.1% | +5.0% |
| Aug 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $19.68 | $21.65 | +10.0% | +4.4% | +2.2% | +1.5% | +0.5% | +6.0% |
| Jun 26 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $20.77 | $20.61 | -0.8% | -3.9% | -1.2% | -0.6% | -1.4% | -1.8% |
| May 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.03 | $22.35 | -3.0% | -4.5% | -7.3% | -10.1% | -10.2% | -2.8% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.03 | $22.35 | -3.0% | -4.5% | -7.3% | -10.1% | -10.2% | -2.8% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.54 | $27.63 | +0.3% | +3.8% | -3.8% | -5.3% | -8.9% | -8.9% |
| Feb 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $28.02 | $27.41 | -2.2% | -1.7% | -3.5% | -3.8% | -2.9% | +0.6% |
| Feb 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $28.52 | $28.45 | -0.2% | -1.8% | -3.5% | -5.2% | -5.5% | -4.6% |
| Feb 16 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $28.52 | $28.45 | -0.2% | -1.8% | -3.5% | -5.2% | -5.5% | -4.6% |
| Jan 30 | BofA Securities | Downgrade | Buy → Neutral | — | $33.76 | $31.47 | -6.8% | -11.6% | -15.9% | -18.9% | -23.7% | -25.8% |
| Jan 25 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $32.93 | $33.06 | +0.4% | -2.6% | -0.9% | +2.5% | -9.3% | -13.8% |
| Jan 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $35.28 | $34.08 | -3.4% | +12.3% | +1.7% | -1.3% | -1.7% | -6.1% |
| Dec 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $39.99 | $40.00 | +0.0% | -8.3% | -6.5% | -7.7% | -6.8% | -1.8% |
| Nov 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $34.96 | $38.46 | +10.0% | +7.4% | +2.2% | +4.2% | +1.0% | -6.3% |
| Oct 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.79 | $43.62 | -0.4% | -3.5% | -3.5% | -9.4% | -22.6% | -18.4% |
No insider trades available.
8-K · 7.01
! Medium
Prothena Corporation plc -- 8-K 7.01: Regulation FD Disclosure
Prothena Corporation authorized a $100 million share repurchase program, signaling management confidence in the stock valuation while potentially supporting future earnings per share.
Feb 27
8-K
Prothena Corporation plc -- 8-K Filing
Prothena's pipeline advanced with Roche initiating the Phase 3 PARAISO trial for prasinezumab in early Parkinson's disease and Novo Nordisk launching Phase 3 CLEOPATTRA for coramitug in ATTR cardiomyopathy, both targeting 2029 completion.
Feb 19
Data updated apr 26, 2026 8:52pm
· Source: massive.com